Objective and method: The survival of the patients with neuroblastoma has improved in last few decades. But still it depends on various clinical and biological factors. To assess the clinical features and trends in survival, the data for 56 newly diagnosed patients between September 1996 and August 2011 from a single center were retrospectively analyzed.
Results Histopathologic subtypes were neuroblastoma (NBL) in 52 patients and ganglioneuroblastoma in 4 patients. The median age was 2.5 years and Male/Female ratio was 1.2/1. Primary tumor sites were abdomen, thorax, and neck with the frequency of 77.4%, 19% and 3.6% respectively. There were 21, 22, 9, 3.1 patients with stage 1, 2, 3, 4, 4S disease and their 5-year survival rates were 100%, 74%, 33%, 6.9%, and 59%, respectively In multivariate analysis, stage 4 disease (P<0.001), abdominal primary tumor site (P<0.001), NBL subtype in histopathology (P=0.001),and responsiveness to chemotherapy (P<0.001) were the determinants of poor prognosis.
Conclusions The survival rates in children with local disease are comparable with the results of developed countries; however, the results in children with advanced disease are still not satisfactory. To improve the outcome, especially in children with advanced disease, more effective chemotherapy regimens and molecular therapies should be investigated. Sharing the knowledge and capacity building to improve the treatment results in NBL are also critical for developing countries.